Newsroom

Press Releases

2018

Jan 12, 2018 - Basking Ridge, NJ (USA)

Ipsen appoints Richard Paulson Executive Vice-President and Chief Executive Officer of Ipsen North America

Download PDF (59KB) >

2017

Oct 12, 2017 - Basking Ridge, NJ (USA)

Ipsen Announces Five Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly

Download PDF (357KB) >

Oct 11, 2017 - Basking Ridge, NJ (USA)

Ipsen Joins PhRMA to Continue Advancing Research and Innovation

Download PDF (274KB) >

Oct 04, 2017 - Basking Ridge, NJ (USA)

Ipsen Announces Four Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Child Neurology Society Annual Meeting

Download PDF (356KB) >

Sep 18, 2017 - Basking Ridge, NJ (USA)

U.S. FDA Approves New Indication for Ipsen's Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome

Download PDF (427KB) >

Sep 15, 2017 - Basking Ridge, NJ (USA)

Ipsen Announces Analysis of Managed Medicaid Data of Children with Cerebral Palsy at Annual Meeting of the American Academy of Cerebral Palsy and Developmental Medicine

Download PDF (237KB) >

Sep 14, 2017 - Basking Ridge, NJ (USA)

Ipsen Announces Oral and Poster Presentations of abobotulinumtoxinA Data at the 2017 Annual Meeting of the American Academy of Cerebral Palsy and Developmental Medicine

Download PDF (329KB) >

Jun 30, 2017 - Basking Ridge, NJ (USA)

Ipsen announces Dysport® (abobotulinumtoxinA) co-promotion agreement with Saol Therapeutics to expand commercial reach in the United States

Download PDF (140KB) >

Jun 16, 2017 - Basking Ridge, NJ (USA)

Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in adults

Download PDF (298KB) >

Apr 19, 2017 - Basking Ridge, NJ (USA)

Ipsen Biopharmaceuticals, Inc. Announces Five Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Annual Meeting of the American Academy of Neurology

Download PDF (348KB) >

Apr 03, 2017 - Paris, Fr (France)

Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals

Download PDF (420KB) >

Mar 21, 2017 - Basking Ridge, NJ (USA)

Blazing New Trails™: Updates in the Care of Children with Cerebral Palsy

Download PDF (329KB) >

Feb 09, 2017 - Basking Ridge, NJ (USA)

Ipsen Biopharmaceuticals, Inc. Announces Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Annual Meeting of the Association of Academic Physiatrists

Download PDF (303KB) >

Jan 18, 2017 - Basking Ridge, NJ (USA)

Ipsen Biopharmaceuticals, Inc. Announces Poster Presentations at ASCO 2017 Gastrointestinal Cancers Symposium

Download PDF (140KB) >

Jan 09, 2017 - Paris, Fr (France)

Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals

Download PDF (84KB) >

2016

Oct 26, 2016 - Basking Ridge, NJ (USA)

Ipsen Biopharmaceuticals, Inc. Announces Data Presentations at the 2016 Annual Meeting of the Child Neurology Society

Download PDF (339KB) >

Oct 19, 2016 - Basking Ridge, NJ (USA)

Ipsen Biopharmaceuticals, Inc. Announces Data Presentations at the Annual Meeting of the American Academy of Physical Medicine & Rehabilitation

Download PDF (185KB) >

Sep 30, 2016 - Basking Ridge, NJ (USA)

Ipsen Biopharmaceuticals, Inc. Announces Nine Poster Presentations at the 2016 North American Neuroendocrine Tumor Society (NANETS) Symposium

Download PDF (150KB) >

Sep 21, 2016 - Basking Ridge, NJ (USA)

Ipsen Announces Data Presentation for Dysport® (abobotulinumtoxinA) at American Academy of Cerebral Palsy and Developmental Medicine

Download PDF (160KB) >

Sep 15, 2016 - Basking Ridge, NJ (USA)

Ipsen Biopharmaceuticals, Inc. Announces Eight Presentations for Dysport® (abobotulinumtoxinA) at the Annual Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine

Download PDF (176KB) >

Aug 01, 2016 - Basking Ridge, NJ (USA)

Ipsen Biopharmaceuticals, Inc. announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients aged two and older

Download PDF (336KB) >

Jun 04, 2016 - Basking Ridge, NJ (USA)

Endocrine Practice Publishes ELECT Phase III Trial Results in Adults with Carcinoid Syndrome

Download PDF (123KB) >

Jun 02, 2016 - Basking Ridge, NJ (USA)

Ipsen Announces Data Presentations of Somatuline® Depot (lanreotide) Injection in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting

Download PDF (372KB) >

Apr 06, 2016 - Basking Ridge, NJ (USA)

Carcinoid Cancer Foundation and Self Care Catalysts Inc. to Provide a Free Digital Patient Support Application for Carcinoid and Neuroendocrine Tumor (NET) Patients, Sponsored in Part by Ipsen Biopharmaceuticals, Inc.

Download PDF (92KB) >

2015

Oct 22, 2015 - Basking Ridge, NJ (USA)

Presentation of Results at the AACPDM Annual Meeting from a Phase III Trial Evaluating an Investigational Use of AbobotulinumtoxinA (Dysport®) in Children with Spastic Equinus Foot Deformity due to Cerebral Palsy

Download PDF (324KB) >

Oct 15, 2015 - Basking Ridge, NJ (USA)

Ipsen Announces Eight Studies of Somatuline® Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors Being Presented at the North American Neuroendocrine Tumor Society (NANETS) Symposium

Download PDF (320KB) >

Oct 01, 2015 - Basking Ridge, NJ (USA)

Ipsen Announces Release of Additional Batch of Increlex® (mecasermin [rDNA origin] injection) in the U.S.

Download PDF (242KB) >

Aug 31, 2015 - Basking Ridge, NJ (USA)

Ipsen announces The Lancet Neurology publishes Dysport® Phase III registration trial results in adult patients with upper limb spasticity (ULS)

Download PDF (140KB) >

Aug 04, 2015 - Sacramento, CA (USA)

Ipsen Biopharmaceuticals, Inc. Receives Statewide Award for Achievements in Product Stewardship

Download PDF (126KB) >

May 14, 2015 - Basking Ridge, NJ (USA)

Ipsen Announces Data Presentations for Somatuline® Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting

Download PDF (342KB) >

Jan 13, 2015 - Basking Ridge, NJ (USA)

Ipsen Biopharmaceuticals To Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline® Depot® (lanreotide), at Gastrointestinal Cancers Symposium

Download PDF (284KB) >

2014

Dec 16, 2014 - Basking Ridge, NJ (USA)

Ipsen announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the treatment of gastroenteropancreatic neuroendocrine tumors

Download PDF (443KB) >

Dec 01, 2014 - Basking Ridge, NJ (USA)

Ipsen Biopharmaceuticals, Inc. Announces FDA Acceptance of Filing for Dysport® (abobotulinumtoxinA) in the Treatment of Upper Limb Spasticity in Adult Patients

Download PDF (204KB) >

Nov 24, 2014 - Basking Ridge, NJ (USA)

Ipsen Biopharmaceuticals, Inc. Announces IPSEN CARES™, An Enhanced Patient Support Program

Download PDF (330KB) >

Nov 14, 2014 - Basking Ridge, NJ (USA)

Ipsen Biopharmaceuticals, Inc. Presents Dysport® (abobotulinumtoxinA) Data at American Academy of Physical Medicine and Rehabilitation Annual Assembly

Download PDF (375KB) >

Nov 06, 2014 - Basking Ridge, NJ (USA)

Ipsen Announces FDA Approval of a New Delivery Device for Somatuline® Depot® (lanreotide) Injection

Download PDF (309KB) >

Nov 05, 2014 - Basking Ridge, NJ (USA)

Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology

Download PDF (361KB) >

Sep 18, 2014 - Basking Ridge, NJ (USA)

Baseline Data from a Phase III Trial in Pediatric Cerebral Palsy Presented at Meeting of the American Academy for Cerebral Palsy and Developmental Medicine

Download PDF (750KB) >

Sep 10, 2014 - Basking Ridge, NJ (USA)

Ipsen Biopharmaceuticals, Inc. Announces Key Medical and Commercial Hires

Download PDF (739KB) >

Sep 01, 2014 - Basking Ridge, NJ (USA)

Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review

Download PDF (395KB) >

Aug 26, 2014 - Basking Ridge, NJ (USA)

Ipsen Announces Second Resupply of Increlex®(mecasermin [rDNA origin] Injection) in the U.S. in 2014

Download PDF (247KB) >

Jul 16, 2014 - Basking Ridge, NJ (USA)

New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors

Download PDF (248KB) >

Jul 01, 2014 - Basking Ridge, NJ (USA)

Ipsen submits marketing authorization applications in the US and Europe for Somatuline® (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Download PDF (98KB) >

May 13, 2014 - Basking Ridge, NJ (USA)

Ipsen announces a step forward in the resupply of Increlex ® (mecasermin [rDNA origin] injection) in the U.S.

Download PDF (368KB) >

May 06, 2014 - Basking Ridge, NJ (USA)

Ipsen Announces Name Change for its Research and Development Affiliate in the U.S. From Biomeasure to Ipsen Bioscience, Inc.

Download PDF (197KB) >

Jan 17, 2014 - Paris, Fr (France)

Ipsen announces at ASCO GI that ELECT® clinical trial of Somatuline® in the control of symptoms in GEP-NET1 patients with carcinoid syndrome met its primary endpoint

Download PDF (136KB) >

Jan 14, 2014 - Paris, Fr (France)

Ipsen to set up its own US oncology team for Somatuline® Depot® (lanreotide) Injection in neuroendocrine tumors

Download PDF (68KB) >

2013

Sep 26, 2013 - Paris, Fr (France)

Ipsen to relocate US R&D activities to Cambridge, MA in 2014

Download PDF (50KB) >

Jul 15, 2013 - Paris, Fr (France)

Ipsen announce a sponsored research agreement with Harvard Medical School to discover novel engineered botulinum toxins for serious neurologic diseases

Download PDF (56KB) >